280 related articles for article (PubMed ID: 29718344)
1. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1.
Gross AM; Singh G; Akshintala S; Baldwin A; Dombi E; Ukwuani S; Goodwin A; Liewehr DJ; Steinberg SM; Widemann BC
Neuro Oncol; 2018 Nov; 20(12):1643-1651. PubMed ID: 29718344
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
3. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study.
Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I
Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501
[TBL] [Abstract][Full Text] [Related]
4. Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
Gross AM; Glassberg B; Wolters PL; Dombi E; Baldwin A; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Whitcomb P; Paul SM; Steinberg SM; Venzon DJ; Martin S; Carbonell A; Heisey K; Therrien J; Kapustina O; Dufek A; Derdak J; Smith MA; Widemann BC
Neuro Oncol; 2022 Nov; 24(11):1978-1988. PubMed ID: 35467749
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
6. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
Dombi E; Solomon J; Gillespie AJ; Fox E; Balis FM; Patronas N; Korf BR; Babovic-Vuksanovic D; Packer RJ; Belasco J; Goldman S; Jakacki R; Kieran M; Steinberg SM; Widemann BC
Neurology; 2007 Feb; 68(9):643-7. PubMed ID: 17215493
[TBL] [Abstract][Full Text] [Related]
7. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
EspĂrito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
8. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1.
Waggoner DJ; Towbin J; Gottesman G; Gutmann DH
Am J Med Genet; 2000 May; 92(2):132-5. PubMed ID: 10797438
[TBL] [Abstract][Full Text] [Related]
9. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
10. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
Ly KI; Merker VL; Cai W; Bredella MA; Muzikansky A; Thalheimer RD; Da JL; Orr CC; Herr HP; Morris ME; Chang CY; Harris GJ; Plotkin SR; Jordan JT
Neurology; 2023 Feb; 100(7):e661-e670. PubMed ID: 36332985
[TBL] [Abstract][Full Text] [Related]
11. Distribution of diffuse plexiform neurofibroma on the body surface in patients with neurofibromatosis 1.
Ehara Y; Koga M; Imafuku S; Yamamoto O; Yoshida Y
J Dermatol; 2020 Feb; 47(2):190-192. PubMed ID: 31849109
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
13. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
14. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas.
Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC
Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281
[TBL] [Abstract][Full Text] [Related]
15. Impact of neurofibromatosis type 1 with plexiform neurofibromas on the health-related quality of life and work productivity of adult patients and caregivers in the UK: a cross-sectional survey.
Yoo HK; Porteous A; Ng A; Haria K; Griffiths A; Lloyd A; Yang X; Kazeem G; Barut V
BMC Neurol; 2023 Nov; 23(1):419. PubMed ID: 37996843
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
[TBL] [Abstract][Full Text] [Related]
17. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
18. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.
Prada CE; Rangwala FA; Martin LJ; Lovell AM; Saal HM; Schorry EK; Hopkin RJ
J Pediatr; 2012 Mar; 160(3):461-7. PubMed ID: 21996156
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.
Weiss B; Widemann BC; Wolters P; Dombi E; Vinks A; Cantor A; Perentesis J; Schorry E; Ullrich N; Gutmann DH; Tonsgard J; Viskochil D; Korf B; Packer RJ; Fisher MJ
Neuro Oncol; 2015 Apr; 17(4):596-603. PubMed ID: 25314964
[TBL] [Abstract][Full Text] [Related]
20. Growth behavior of plexiform neurofibromas after surgery.
Nguyen R; Ibrahim C; Friedrich RE; Westphal M; Schuhmann M; Mautner VF
Genet Med; 2013 Sep; 15(9):691-7. PubMed ID: 23598713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]